SEARCH

SEARCH BY CITATION

References

  • 1
    Buller HR., Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S28S.
  • 2
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S33S.
  • 3
    Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 184353.
  • 4
    Yavin YY, Wolozinsky M, Cohen AT. New antithrombotics in the prevention of thromboembolic disease. Eur J Intern Med 2005; 16: 25766.
  • 5
    Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 236875.
  • 6
    The Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2: 4753.
  • 7
    The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695702.
  • 8
    Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AEM, Cariou R, Leeuwenkamp O, Lensing AWA, for the Matisse investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 86773.
  • 9
    Buller HR, Cohen AT, Davidson B, Decousus H, Gallus A, Gent M, Pillion G, Piovella F, Prins MH, Raskob G. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094104.
  • 10
    Van Dongen CJ, Van Den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; 4: CD001100.